Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bloomage BioTechnology Corporation Limited (688363.SS)
Jinan, SH, CN
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under the Hybloom, miniHA, microHA, Hyacross, Hyacolor, and cationHA. The company also provides food-grade sodium hyaluronate for use in food/healthy food/dietary supplements under the HAPLEX name, as well as food-grade gamma aminobutyric acid under the Gabarelax name; hyaluronic acid for oral care under the Biomoist name; and animal care products under the HYAPET names. Bloomage BioTechnology Corporation Limited was founded in 2000 and is based in Jinan, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.03% | -0.68% | -2.73% | -14.35% | -20.29% | -6.02% | -15.79% | -56.79% | -80.93% | -51.76% | -51.76% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%-21.8% Q1'26: -23.1% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+69.4% ★ Q1'26: -33.3% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+3.3% ★ Q1'26: +3.5% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+8.1% Q1'26: +8.5% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+4.7% Q1'26: +4.2% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-1.1% ★ Q1'26: -4.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.33× ★ Q1'26: 1.04× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 7 Rev. Ana. 7 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
650.87M
est: 616.58M (+5.6%)
|
733.12M
est: 837.00M (-12.4%)
|
818.05M
est: 970.47M (-15.7%)
|
1.26B
est: 1.17B (+7.8%)
|
1.89B
est: 1.88B (+0.4%)
|
2.63B
est: 2.53B (+3.9%)
|
4.95B
est: 4.64B (+6.6%)
|
6.36B
est: 6.58B (-3.3%)
|
6.08B
est: 5.81B (+4.6%)
|
5.37B
est: 5.62B (-4.4%)
|
4.20B
est: 4.57B (-8.1%)
|
4.25B
4.00B – 4.52B
-7.0% YoY
|
4.77B
3.83B – 5.62B
+12.3% YoY
|
4.95B
4.84B – 5.06B
+3.7% YoY
|
| EBITDA |
287.19M
est: 104.51M (+174.8%)
|
337.89M
est: 141.86M (+138.2%)
|
321.08M
est: 164.49M (+95.2%)
|
528.94M
est: 198.55M (+166.4%)
|
729.43M
est: 318.30M (+129.2%)
|
740.23M
est: 429.64M (+72.3%)
|
866.92M
est: 786.68M (+10.2%)
|
1.12B
est: 1.11B (+0.8%)
|
775.49M
est: 851.35M (-8.9%)
|
465.45M
est: 822.97M (-43.4%)
|
698.04M
est: 669.47M (+4.3%)
|
622.78M
586.59M – 661.96M
-7.0% YoY
|
699.27M
560.83M – 823.16M
+12.3% YoY
|
725.01M
708.63M – 741.38M
+3.7% YoY
|
| EBIT |
246.95M
est: 85.54M (+188.7%)
|
303.43M
est: 116.12M (+161.3%)
|
278.63M
est: 134.64M (+106.9%)
|
482.06M
est: 162.52M (+196.6%)
|
669.03M
est: 260.54M (+156.8%)
|
670.05M
est: 351.68M (+90.5%)
|
746.46M
est: 643.93M (+15.9%)
|
961.48M
est: 912.44M (+5.4%)
|
570.18M
est: 604.57M (-5.7%)
|
232.36M
est: 584.42M (-60.2%)
|
340.22M
est: 475.41M (-28.4%)
|
442.26M
416.56M – 470.08M
-7.0% YoY
|
496.58M
398.26M – 584.55M
+12.3% YoY
|
514.85M
503.23M – 526.48M
+3.7% YoY
|
| Net Income |
190.39M
est: 279.22M (-31.8%)
|
269.43M
est: 334.99M (-19.6%)
|
222.27M
est: 369.63M (-39.9%)
|
423.86M
est: 470.82M (-10.0%)
|
585.61M
est: 590.57M (-0.8%)
|
645.84M
est: 651.08M (-0.8%)
|
782.33M
est: 791.18M (-1.1%)
|
970.92M
est: 922.30M (+5.3%)
|
592.56M
est: 509.71M (+16.3%)
|
174.27M
est: 398.38M (-56.3%)
|
292.06M
est: 351.88M (-17.0%)
|
399.53M
347.91M – 451.14M
+13.5% YoY
|
575.57M
382.86M – 747.58M
+44.1% YoY
|
590.87M
499.78M – 752.23M
+2.7% YoY
|
| SGA |
248.98M
est: 332.88M (-25.2%)
|
211.35M
est: 451.87M (-53.2%)
|
294.80M
est: 523.93M (-43.7%)
|
448.20M
est: 632.43M (-29.1%)
|
701.13M
est: 1.01B (-30.8%)
|
1.26B
est: 1.37B (-8.2%)
|
2.74B
est: 2.51B (+9.2%)
|
3.44B
est: 3.55B (-3.2%)
|
3.33B
est: 2.90B (+15.0%)
|
3.12B
est: 2.80B (+11.3%)
|
1.13B
est: 2.28B (-50.2%)
|
2.12B
2.00B – 2.25B
-7.0% YoY
|
2.38B
1.91B – 2.80B
+12.3% YoY
|
2.47B
2.41B – 2.52B
+3.7% YoY
|
| EPS |
0.57
est: 0.58 (-1.2%)
|
0.74
est: 0.69 (+6.9%)
|
0.46
est: 0.76 (-39.4%)
|
0.98
est: 0.97 (+0.8%)
|
1.34
est: 1.22 (+9.8%)
|
1.35
est: 1.35 (+0.4%)
|
1.63
est: 1.63 (-0.3%)
|
2.02
est: 2.04 (-1.1%)
|
1.23
est: 1.06 (+16.1%)
|
0.36
est: 0.84 (-57.0%)
|
0.61
est: 0.74 (-17.5%)
|
0.84
0.73 – 0.94
+14.2% YoY
|
1.12
0.80 – 1.56
+33.2% YoY
|
1.29
1.04 – 1.57
+15.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.08% | 30.6K | 0.65% |
| 2 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 6.1K | 0.15% |
| 3 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 155.5K | 0.19% |
| 4 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 12.6K | 0.58% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 17.7K | 0.44% |
| 6 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 101.3K | 0.17% |
| 7 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 101.3K | 0.17% |
| 8 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 179.3K | 0.06% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 19.4K | 0.48% |
| 10 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 43.7K | 0.26% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gao Yi | Deputy General Manager | — | female |
| Hui Wang | Chief Accountant, Deputy GM, Chief Financial Officer & Financial Director | — | male |
| Jiajun Guo | Deputy GM & Director | — | male |
| Mao Gong Xiang | Deputy General Manager | — | male |
| Songyan Zou | Director & Vice President of Business | — | male |
| Xueping Guo | Deputy GM of Core Technician & Director | — | male |
| Yan Zhao | Chairman & GM | — | female |
| Yizheng Li | Deputy GM, Secretary of the Board of Directors & Director | — | male |
| Yuan Fan | Director & Vice President of Business | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688363.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
